Decoding the RNA Operating System of the Cell with Up-to-date miRNA Profiling Service
News Sep 11, 2007
febit biotech gmbh has announced the launch of its new miRNA profiling service. With day-to-day synthesis capability and broad flexibility of content, febit’s Geniom Biochips reflect up-to-date version of miRBase, the miRNA database at the Sanger Institute.
In addition the biochip content is completely customizable to include capture probes for researchers own miRNA targets.
The customer can choose the degree of autonomy and use three types of services: Preset Geniom miRNA Biochip which is based on the latest miRBase Version 10.0; the same biochip plus some sequences specified by the customer; or a biochip which contains completely customized oligonucleotides for microarray analysis.
miRNA profiling can be put out as a service which is offered by febit, or can be analyzed independently by ordering Geniom Ready-to-Go Biochips or even use the possibility to buy the Geniom Platform to produce up-to-date biochips in the researcher’s lab.
Ph.D. Adam Grundhoff from the Heinrich-Pette-Institute for Experimental Virology and Immunology at the University of Hamburg (Germany) stated: “For our evaluation studies we used preset Geniom Biochips based on the miRBase Version 10.0 content with additional viral sequences which are relevant for our research. The chips were analyzed with our samples by febit and we are very excited about the short handling time and the high quality results.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.